SLC5A2 and heart failure: A recent meta-analysis79 that included 6 CVOTs of patients with diabetes and 4 CVOTs of patients with and without diabetes found that eGFR did not alter the relative benefit of SGLT2 inhibitors for MACE and heart failure outcomes2,74,78,80–82; however, a greater relative benefit was reported for MACE in those with higher baseline albuminuria (ACR>300mg/g HR 0.74 95%CI 0.66, 0.84; ACR 30-300mg/g HR 0.95 [95%CI 0.82, 1.10]) ACR<30mg/g HR 0.87 [95%CI 0.77, 0.98]).